Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, unveiled an expanded portfolio of cardiac imaging agent products that offers Myoview, Cardiolite and a new generic sestamibi product from Cardinal Health.
The company announced the product portfolio expansion as part of its strategy to broaden choice for its customers.
John Rademacher, president and general manager of Nuclear and Specialty Pharmacy Services for Cardinal Health said, Cardinal Health is now the only company that can offer all three technetium-based heart agents across a national network of nearly 160 nuclear pharmacies. By increasing choice for our customers, we continue to add differentiated value from our industry leading foundation of service and quality. Although we recognize the serious implications of the current global molybdenum shortage, we believe the introduction of this additional product is an important long-term benefit for nuclear medicine practitioners and their patients. Cardinal Health will continue to work with industry leaders and the Society for Nuclear Medicine to address current, mid-range and long-term solutions for molybdenum supply.
